| Clinical data | |
|---|---|
| Routes of administration | Oral |
| ATC code |
|
| Legal status | |
| Legal status |
|
| Identifiers | |
| |
| CAS Number |
|
| PubChemCID | |
| ChemSpider | |
| UNII | |
| ChEMBL | |
| CompTox Dashboard(EPA) | |
| Chemical and physical data | |
| Formula | C15H19NO |
| Molar mass | 229.323 g·mol−1 |
| 3D model (JSmol) | |
| Chirality | Racemic mixture |
| |
Pronethalol (also known asnethalide orcompound 38,174; trade nameAlderlin) was an early non-selectivebeta blocker clinical candidate. It was the first beta blocker to be developed byJames Black and associates atImperial Chemical Industries, and the first to enter clinical use, in November 1963.[1]
However, it was never used widely due tocarcinogenicity in mice, which was thought to result from formation of a carcinogenicnaphthalene epoxide metabolite,[2] and was superseded bypropranolol from 1965 onward.[1]
Thisantihypertensive-related article is astub. You can help Wikipedia byexpanding it. |